增长失速、盈利触底 悦康药业赴港为求“续命”？

Core Viewpoint - Yuekang Pharmaceutical Group Co., Ltd. has submitted an application for H-share listing on the Hong Kong Stock Exchange, marking a significant step in its "A+H" dual-platform listing strategy, which aims to address its financial challenges and support R&D innovation [1][3]. Group 1: Company Overview - Yuekang Pharmaceutical, listed on the STAR Market, is transitioning to a dual listing in Hong Kong to create an international financing platform [1][3]. - The company has faced declining performance, with revenue dropping from 4.542 billion yuan in 2022 to 3.781 billion yuan in 2024, and net profit plummeting from 335 million yuan to 124 million yuan in the same period [6][7]. Group 2: Financial Challenges - The company's core product, Ginkgo Biloba Extract Injection, has seen a price reduction of approximately 53% due to regulatory scrutiny, leading to significant revenue loss and a quarterly loss of 86.01 million yuan in Q4 2024 [6][7]. - The reliance on a single product has weakened the company's risk resilience, exposing vulnerabilities in its product pipeline [7]. Group 3: Strategic Initiatives - The funds raised from the H-share listing are intended for R&D innovation and operational capital, which could alleviate financial pressures and revitalize stalled projects [10]. - The dual listing structure is expected to enhance liquidity and provide a valuation anchor based on the existing A-share market [10]. Group 4: Market Sentiment and Risks - Investors are cautious, weighing the potential for recovery against ongoing risks, including high sales costs and governance concerns stemming from the controlling shareholder's legal issues [9][11]. - The market perceives the recent price adjustments as a potential turning point, suggesting that the worst may be over, but uncertainties regarding profitability recovery remain [10][11]. Group 5: IPO Details - The IPO timeline is pending, with details such as the offering price and allocation mechanisms yet to be announced [13]. - The company plans to establish a green shoe mechanism to stabilize pricing, allowing underwriters to exercise an over-allotment option of up to 15% of the initial offering size [13].